Cardiovascular and Kidney Outcomes of Tirzepatide versus Semaglutide in Stage 2 Cardiovascular-Kidney-Metabolic Syndrome: A Propensity Score-matched Cohort Study
Cardiovascular-kidney-metabolic (CKM) syndrome describes the overlapping burden of metabolic dysfunction, chronic kidney disease, and cardiovascular disease. Tirzepatide and semaglutide are both recommended for patients with type 2 diabetes and obesity, yet no randomized trial has directly compared their effect on...